Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial

Previous clinical trials have not evaluated improvement in nail psoriasis as a primary end point.

http://ift.tt/2yOeM2N